Research.Patient.info
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD) research hub
2 indexed studies · 1 currently recruiting
- recruitingPHASE3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
This study is testing a new medicine, tabelecleucel, for people who have a condition called EBV+ PTLD. This condition can happen after an organ transplant or a stem cell transplant and treatment with rituximab hasn't worked. The study wants to see if tabelecleucel is safe and effective.
United States · Australia · Austria - active not recruitingPHASE2
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
This study is looking at a new treatment called tabelecleucel for diseases linked to the Epstein-Barr virus (EBV). These can include certain cancers or conditions where the immune system isn't working properly. The study wants to see how well tabelecleucel works and if it's safe.
United States · Austria · Belgium